---
schema_version: "secwatch.filing_event.v1"
accession: "0001326190-23-000020"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2023-03-27T23:59:59+00:00"
generated_at: "2026-06-17T14:34:24.009536+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Altimmune appoints former GSK executive Catherine Sohn to board of directors

## Summary
- Catherine Sohn, Pharm.D., appointed to Altimmune's Board effective March 23, 2023.
- Dr. Sohn currently serves on boards of Jazz Pharma, Axcellea Health, and Maze Therapeutics.
- She was formerly SVP Worldwide Business Development at GSK's Consumer Healthcare division.
- Received initial option award for 47,000 shares and annual cash retainer of $40,000.
- CEO Vipin Garg says her experience in peptide therapeutics for obesity and liver disease will be valuable.

## SEC filing metadata
- accession: 0001326190-23-000020
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2023-03-27T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000020/0001326190-23-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000020/alt-20230323x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326190-23-000020
- JSON: https://secwatch.observer/filing/0001326190-23-000020.json
- Plain text: https://secwatch.observer/filing/0001326190-23-000020.txt

## Key facts
- Executive change
  Catherine Sohn was appointed as Director at Altimmune, Inc..
  - Action: appointed
  - Role: Director
  source text: appointed Catherine Sohn, Pharm.D. as a director of the Company’s Board, effective March 23, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326190/000132619023000020/0001326190-23-000020-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.